Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

Summary

This research is being conducted to understand if treatment can be tailored for participants with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking status) combined with an investigational HPV blood test. The names of the test and treatments involved in this study are: * NavDx® HPV ctDNA testing (HPV blood test) * Radiation therapy * Chemotherapy: Cisplatin, or Carboplatin and Paclitaxel (not all participants receive any or all of these agents)

Timeline

Start

2021-07-02

Primary completion

2030-06-01

Completion

2032-06-01

Publications

• Hanna GJ, Gupta TR, Trippa L, Rettig EM, Margalit DN, Tishler RB, Pashtan I, Kim E, Droznin A, Gunasti L, Maddox R, Minken J, Mukundan D, Sehgal K, Dennis MJ, O'Connor T, Qian JM, Boyd GH, Saraf A, Massiel Gil D, Sethi RK, Annino DJ, Goguen LA, Guenette JP, Bakhtiar M, Jo VY, Wong K, Uppaluri R, Haddad RI, Schoenfeld JD. Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial. Nat Commun. 2026 May 7. doi: 10.1038/s41467-026-72984-7. Online ahead of print.

Drugs

Indications